APYX

Apyx Medical Corporation · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-10

Figures on this page computed 2026-11-08 13:21 UTC

Last close

3.06USD

Market data, 2026-11-05

APYX: weekly closes from 3.03 on 2026-08-14 to 3.06 on 2026-11-05, a move of +1.0%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-05

Over that span: +1.0%

Except where said otherwise: 10-K for 2025, filed 2026-03-10

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
-21.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
-17.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
2.71Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.42 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.56x

1.45x

0.69x

2.54x

0.59x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales1.56x
Its own average over 10 years, 33.8M.
Profit1.45x
Its own average over 10 years, -7.7M.
Free cash flow0.69x
Its own average over 10 years, -13.1M.
Debt2.54x
Its own average over 8 years, 15.5M.
Price0.59x
Its own average over 8 years, 5. Market data, 2026-11-05

Debt is furthest from its own average, at 2.54 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	116.0	114.5
2018-12-31	189.2	125.2
2019-12-31	320.2	124.1
2020-12-31	314.2	124.6
2021-12-31	550.1	125.1
2022-12-31	504.7	125.7
2023-12-31	593.6	126.1
2024-12-31	545.4	129.5
2025-12-31	599.2	149.7

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001437749-26-007471
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001437749-26-007471
Reported in: USD

The filing itself

Figures behind the shape

Growth

13.8%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate13.8%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income52.2%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-77.1%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on equity-77.1%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on assets-16.8%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself

Margins

62.5%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin62.5%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Operating margin-12.2%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Net margin-21.2%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Free cash flow margin-17.3%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself

Price

8.3x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
Price to book8.3x10-Q for 2025, filed 2026-08-06
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001437749-26-026346
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-06
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-10
The filing itself
Price to sales ratio2.3x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself

Safety

2.71

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity2.71
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-06
The filing itself
Current ratio5.0010-Q for 2025, filed 2026-08-06
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001437749-26-026346
Reported in
USD
- 10-Q for 2025, filed 2026-08-06
- 10-Q for 2025, filed 2026-08-06
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Altman Z-Score0.83
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001437749-26-007471
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.